Author
Listed:
- Xiaochen Chen
(Department of Epidemiology, School of Public Health and the Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai 200032, China
Key Laboratory of Health Technology Assessment of Ministry of Health, Fudan University, Shanghai 200032, China
Equally contributed first authors.)
- Xing Liu
(Department of Epidemiology, School of Public Health and the Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai 200032, China
Equally contributed first authors.)
- Song Duan
(Dehong Prefecture Center for Disease Control and Prevention, Mangshi 678400, China)
- Renhai Tang
(Dehong Prefecture Center for Disease Control and Prevention, Mangshi 678400, China)
- Sujuan Zhou
(Department of Epidemiology, School of Public Health and the Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai 200032, China)
- Runhua Ye
(Dehong Prefecture Center for Disease Control and Prevention, Mangshi 678400, China)
- Yuecheng Yang
(Dehong Prefecture Center for Disease Control and Prevention, Mangshi 678400, China)
- Jibao Wang
(Dehong Prefecture Center for Disease Control and Prevention, Mangshi 678400, China)
- Shitang Yao
(Dehong Prefecture Center for Disease Control and Prevention, Mangshi 678400, China)
- Na He
(Department of Epidemiology, School of Public Health and the Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai 200032, China
Key Laboratory of Health Technology Assessment of Ministry of Health, Fudan University, Shanghai 200032, China)
Abstract
Background: HIV and HCV coinfection leads to accelerated liver fibrosis, in which microbial translocation and systemic inflammation might play important roles. Objective: This study aimed to provide an extensive profile of the plasma microbial translocation and inflammation biomarkers associated with advanced liver fibrosis among HIV–HCV-coinfected patients. Methods: This cross-sectional study recruited 343 HIV–HCV-coinfected patients on combination antiretroviral therapy (cART) from a rural prefecture of Yunnan province in Southwest China. The plasma concentrations of sCD14 and 27 cytokines and chemokines were assayed and compared against advanced or mild levels of liver fibrosis. Results: Of the 343 HIV–HCV-coinfected patients, 188 (54.8%) had severe or advanced liver fibrosis (FIB-4 > 3.25). The patients with advanced liver fibrosis (FIB-4 > 3.25 vs. FIB-4 ≤ 3.25) had higher plasma levels of interleukin (IL)-1β, IL-6, IL-7, IL-9, IL-12, IL-15, IL-17, granulocyte macrophage colony stimulating factor (GM-CSF), Interferon-γ (IFN-γ), tumor necrosis factor (TNF-α), IL-4, IL-10, IL-13, fibroblast growth factor 2 (FGF-basic), and Monocyte chemoattractant protein-1 (MCP-1). Multivariable logistic regression models showed that advanced liver fibrosis was associated with an increased plasma level of IL-1β, IL-6, IL-7, IL-12, IL-17, GM-CSF, IFN-γ, IL-4, IL-10, MCP-1, Eotaxin, and FGF-basic, with FGF-basic continuing to be positively and significantly associated with advanced liver fibrosis, after Bonferroni correction for multiple comparisons (adjusted odds ratio (aOR) = 1.92; 95%CI: 1.32–2.81; p = 0.001). Plasma sCD14 was also significantly associated with advanced liver fibrosis (aOR = 1.13; 95%CI: 1.01–1.30; p = 0.049). Conclusions: HIV–HCV-coinfected patients are living with a high prevalence of advanced liver fibrosis which coexists with a mixture of elevated plasma inflammation and microbial translocation biomarkers. The significant associations of advanced liver fibrosis with FGF-basic and sCD14 may reveal pathogenic mechanisms and potential clinical intervention targets for liver fibrosis in HCV–HIV coinfection.
Suggested Citation
Xiaochen Chen & Xing Liu & Song Duan & Renhai Tang & Sujuan Zhou & Runhua Ye & Yuecheng Yang & Jibao Wang & Shitang Yao & Na He, 2020.
"Plasma Inflammatory Biomarkers Associated with Advanced Liver Fibrosis in HIV–HCV-Coinfected Individuals,"
IJERPH, MDPI, vol. 17(24), pages 1-12, December.
Handle:
RePEc:gam:jijerp:v:17:y:2020:i:24:p:9474-:d:463983
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:17:y:2020:i:24:p:9474-:d:463983. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.